CervoMed (CRVO) vs Edesa Biotech (EDSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edesa Biotech (EDSA) has outperformed CervoMed (CRVO) over the past year, gaining 34.6% versus a loss of 63.1%. Over five years, CRVO leads with a -90.9% price change compared with -93.3% for EDSA. CervoMed is the larger company by market cap ($49.7 million vs $48.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | EDSA |
|---|---|---|
| Share price | $3.29 | $3.60 |
| Market cap | $49.67M | $48.64M |
| 1-day change | +0.15% | -1.64% |
| YTD return | -58.48% | +157.75% |
| 1-year return | -63.15% | +34.56% |
| 5-year return | -90.89% | -93.31% |
| EPS (TTM) | $-3.21 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.00 | $20.32 |
| 52-week low | $2.13 | $0.72 |
| Distance from 52-week high | -67.15% | -82.28% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +368.80% | +353.61% |
| Average volume | 339.08K | 61.89K |
| Shares outstanding | 15.12M | 13.51M |
| Employees | 15 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed CRVO by 97.7 percentage points over the past year.
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
CRVO vs EDSA FAQ
Which is bigger, CervoMed or Edesa Biotech?
CervoMed (CRVO) is larger, with a market capitalization of $49.67M compared with $48.64M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, CRVO or EDSA?
EDSA returned +34.56% over the past 12 months, compared with -63.15% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and Edesa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.